Foghorn Therapeutics FHTX
NASDAQ FHTX
$4.91 +0.05 (+0.92%)
As of: Sep 4, 2026 · 2:18 PM EDT

Foghorn Therapeutics (FHTX) Receivables - Net (2021)

Foghorn Therapeutics (FHTX) posted quarterly Receivables - Net of $300.0 million for Q4 2021.

Analysis

Foghorn Therapeutics (FHTX) Receivables - Net (2021) Analysis & Trends

Foghorn Therapeutics' Receivables - Net history runs 1 years deep, the most recent figure standing at $300.0 million for Q4 2021.

  • In Q4 2021, Receivables - Net changed N/A year-over-year to $300.0 million; the TTM figure through Dec 2021 stood at $300.0 million (changed N/A YoY), while the FY2021 annual figure was $300.0 million, changed N/A from the prior year.
  • Receivables - Net for Q4 2021 stood at $300.0 million.
  • The five-year high for Receivables - Net was $300.0 million in Q4 2021, with the low at $300.0 million in Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.92 Bn 131.07 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn
3 Argenx Se 63.55 Bn 58.37 Bn 1.37 Bn
4 Moderna 58.26 Bn 53.13 Bn 52.00 Mn
5 Revolution Medicines 44.08 Bn 44.08 Bn -
6 BeOne Medicines 39.98 Bn 34.89 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.32 Bn 32.01 Bn 992.69 Mn
8 Royalty Pharma 28.42 Bn 27.59 Bn -
9 Insmed 27.41 Bn 26.25 Bn 358.27 Mn
10 Foghorn Therapeutics 346.79 Mn 278.71 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 300.00 Mn